Pineda-Cásarez F, Durán-Ortiz M, Gómez-de la Cruz CA, Soto-Becerril OA, del Bosque-Méndez JE, Rodríguez-Perales MA

Language: Spanish
References: 0
Page: 59-63
PDF size: 134.05 Kb.

ABSTRACT

Background: The use of thyroid stimulating hormone (TSH) as a prognostic factor for therapeutic decision is controversial, there is no standardized cohort point. Despite the existence of the ACR TIRADS and the Bethesda system for decision-making, there are borderline scenarios where the TSH could tip the surgical decision.
Objective: To determine in thyroid pathology the relationship between the serum thyroglobulin levels and malignancy to regulate behavior.
Material and Method: A retrospective, descriptive, observational and cross-sectional study, which was carried out at the Regional Hospital General Ignacio Zaragoza and Hospital Juárez de México (Mexico City), reviewing the files of the outpatient clinic of surgical Oncology from 2014 to 2018, where the relationship between TSH and the presence of malignancy was observed.
Results: In 86 patients, the average TSH levels were 3.9 ± 2.27 UI/dL. Nonparametric tests were applied with SPSS version 25 statistical program calculating Mann-Whitney U, which confirmed serum TSH levels › 2.1 mUI in patients with reports of malignancy with a statistical significance of 0.05.
Conclusions: Patients with a Bethesda 1, 3 and 4 categories, which had a TSH greater than 2.1 mUI, are surgery candidates because of the increased risk of having cancer.